TOLEDO, Ohio – (BUSINESS WIRE) – NAMSA®, the world’s only Medical Research Organization (MRO) that accelerates medical device development through integrated laboratory, clinical research and regulatory consulting services, announced today that it has been recognized for excellence in clinical research and honored for the second consecutive year as a 2018 “CRO Leadership Award” winner.
The CRO Leadership Awards are issued by Life Science Leader Magazine and are based on data gathered by Industry Standard Research, a full-service biotechnology market research firm. Recipients of this esteemed award are evaluated against 70 CROs and selected based on feedback from Sponsor decision-makers that have utilized clinical research services within the last 18 months. NAMSA was ranked as a CRO industry leader in the categories of Capabilities, Compatibility, Expertise, Quality and Reliability, with top performance noted in the areas of Data Quality and Access, Meeting Project Timelines, Operational Excellence, and Responsiveness.
“The CROs receiving an award this year are truly at the top of their class, and are deserving of the recognition they receive. Being selected as a winner in any category displays a high level of expertise within clinical trials and a dedication to serving the needs of medical technology companies and their patients,” said Ed Miseta, Executive Editor, Life Science Leader.
“This honor is a result of our dedicated focus on providing high quality services and using client resources judiciously to deliver time and cost savings throughout the full medical device development continuum. By combining our scientific knowledge with NAMSA’s Medical Research Organization (MRO®) Approach, clients achieve clinical endpoints more quickly and are empowered to make effective decisions that accelerate the global delivery of life-changing medical technologies,” commented NAMSA President & CEO, John Gorski.
For over 50 years, NAMSA has partnered with thousands of global customers to provide the most critical research services required to accelerate time-to-market and reduce costs for medical device innovation and research. Consistently recognized as an industry leader, with an established track record of providing clients development savings of up to 23 months and $17M in costs, NAMSA is dedicated to partnering with global manufacturers to bring novel medical technology to the marketplace in the most efficient manner possible.
NAMSA operates 13 offices throughout North America, Europe, the Middle East and Asia, and employs 1,000 highly-experienced laboratory, clinical research and regulatory consulting Associates.